Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Fig. 2

Methylation profile of the selected CpGs in responder and non-responder group in the discovery cohort (DC). From the 450K array, ten CpGs corresponding to nine genes were found in CpG islands or in the promoter regions with a standard deviation intragroup ≤ 20% and with a consistent DNA methylation profile of consecutive CpGs. These candidate genes were LOC641519, LEF1, HOXA5, EVC2, TLX3, and CDKL2 with high methylation in non-responder group and genes FERD3L, CHL1, and TRIP10 with high methylation in responder group. Consecutive CpGs to the CpGs of interest were evaluated in each gene by the 450K array. Points represent mean methylation values from patients

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us